Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News

Index by author

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

  1. Ali, Lestat

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  2. Almåsbak, Hilde

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  3. Antonescu, Cristina R.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  4. Armenta, Paul M.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  5. Askin, Kayleigh N.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

B

  1. Bajor, Malgorzata

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  2. Balachandran, Vinod

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  3. Baloyan, David

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  4. Beckman, Michael J.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  5. Blake, Zoë

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  6. Blomberg, Olga

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  7. Bossé, Dominick

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  8. Brandao, Raphael

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  9. Brandt, Ludwig

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  10. Bruck, Patrick T.

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

C

  1. Chou, Chun

    1. Cancer Immunology at the Crossroads | AuthorChoice
      Re(de)fining Innate Lymphocyte Lineages in the Face of Cancer
      Chun Chou and Ming O. Li
      Cancer Immunol Res April 1 2018 6 (4) 372-377; DOI:10.1158/2326-6066.CIR-17-0440

  2. Choueiri, Toni K.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  3. Clement, Dennis

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  4. Correia, Daniel V.

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

D

  1. Davalos-Salas, Mercedes

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  2. Davari, Danielle R.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  3. DeMatteo, Ronald P.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  4. De Velasco, Guillermo

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  5. Desbien, Anthony L.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  6. Dias, Sérgio

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

  7. Didara, Zrinka

    1. Research Articles | AuthorChoice
      NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
      Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
      Cancer Immunol Res April 1 2018 6 (4) 458-466; DOI:10.1158/2326-6066.CIR-17-0183

      Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

  8. Dijkstra, Christine

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  9. Dougan, Michael

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  10. Dougan, Stephanie K.

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  11. Drake, Charles G.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

    2. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  12. Dubensky, Thomas W.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

E

  1. Edlinger, Leo

    1. Research Articles | AuthorChoice
      NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
      Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
      Cancer Immunol Res April 1 2018 6 (4) 458-466; DOI:10.1158/2326-6066.CIR-17-0183

      Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

  2. Eissmann, Moritz F.

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  3. Ernst, Matthias

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  4. Esancy, Camden L.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

F

  1. Francica, Brian J.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  2. Fu, Yichun

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

G

  1. Gao, Xin

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  2. Gartrell, Robyn D.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  3. Ghasemzadeh, Ali

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  4. Goodridge, Jodie

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  5. Gotthardt, Dagmar

    1. Research Articles | AuthorChoice
      NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
      Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
      Cancer Immunol Res April 1 2018 6 (4) 458-466; DOI:10.1158/2326-6066.CIR-17-0183

      Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

  6. Graczyk-Jarzynka, Agnieszka

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

H

  1. Hamana, Hiroshi

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  2. Hamieh, Lana

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  3. Harshman, Lauren C.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  4. Hart, Thomas D.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  5. Hayakawa, Yoshihiro

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  6. Hayday, Adrian C.

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

  7. Hix Glickman, Laura

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  8. Hoel, Hanna Julie

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  9. Horst, Basil A.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

I

  1. Ingram, Jessica R.

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  2. Izaki, Daisuke

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

J

  1. Jeong, Hee-Jin

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  2. Jia, Dan Tong

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

K

  1. Katayama, Ichiro

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  2. Kaufman, Howard L.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  3. Kishi, Hiroyuki

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  4. Kobayashi, Eiji

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  5. Krajewski, Katherine M.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  6. Kyle-Cezar, Fernanda

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

  7. Kyte, Jon-Amund

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

L

  1. Lalani, Aly-Khan A.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  2. Leong, Meredith L.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  3. Li, Gen

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  4. Li, Ming O.

    1. Cancer Immunology at the Crossroads | AuthorChoice
      Re(de)fining Innate Lymphocyte Lineages in the Face of Cancer
      Chun Chou and Ming O. Li
      Cancer Immunol Res April 1 2018 6 (4) 372-377; DOI:10.1158/2326-6066.CIR-17-0440

  5. Loo, Jennifer K.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  6. Lu, Yan

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  7. Lynn, Rachel C.

    1. Letters to the Editor
      Neurotoxicity Associated with a High-Affinity GD2 CAR—Letter
      Robbie G. Majzner, Evan W. Weber, Rachel C. Lynn, Peng Xu and Crystal L. Mackall
      Cancer Immunol Res April 1 2018 6 (4) 494-495; DOI:10.1158/2326-6066.CIR-18-0089

  8. Lyu, Fulian

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

M

  1. Mackall, Crystal L.

    1. Letters to the Editor
      Neurotoxicity Associated with a High-Affinity GD2 CAR—Letter
      Robbie G. Majzner, Evan W. Weber, Rachel C. Lynn, Peng Xu and Crystal L. Mackall
      Cancer Immunol Res April 1 2018 6 (4) 494-495; DOI:10.1158/2326-6066.CIR-18-0089

  2. Majzner, Robbie G.

    1. Letters to the Editor
      Neurotoxicity Associated with a High-Affinity GD2 CAR—Letter
      Robbie G. Majzner, Evan W. Weber, Rachel C. Lynn, Peng Xu and Crystal L. Mackall
      Cancer Immunol Res April 1 2018 6 (4) 494-495; DOI:10.1158/2326-6066.CIR-18-0089

  3. Malmberg, Karl-Johan

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  4. Maltbaek, Joanna H.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  5. Marciscano, Ariel E.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  6. Mariadason, John M.

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  7. Marks, Douglas K.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  8. Martini, Dylan J.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  9. Masson, Frederick

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  10. McDermott, David F.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  11. McGregor, Bradley

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  12. McKay, Rana R.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  13. McWhirter, Sarah M.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  14. Medina, Benjamin D.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  15. Mensurado, Sofia

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

  16. Menzl, Ingeborg

    1. Research Articles | AuthorChoice
      NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
      Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
      Cancer Immunol Res April 1 2018 6 (4) 458-466; DOI:10.1158/2326-6066.CIR-17-0183

      Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

  17. Michaelson, M. Dror

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  18. Milone, Michael C.

    1. Letters to the Editor
      Neurotoxicity Associated with a High-Affinity GD2 CAR—Response
      Sarah A. Richman and Michael C. Milone
      Cancer Immunol Res April 1 2018 6 (4) 496-497; DOI:10.1158/2326-6066.CIR-18-0090

  19. Monod, Anthea

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  20. Moral, John A.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  21. Mosaheb, Munir M.

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  22. Mouradov, Dmitri

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  23. Muraguchi, Atsushi

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  24. Murahashi, Mutsunori

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

N

  1. Nagata, Takuya

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  2. Nguyen, Paul M.

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  3. Nguyen, Quang-De

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  4. Nishikawa, Hiroyoshi

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  5. Norell, Haakan

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

  6. Norton, Craig K.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  7. Nóbrega-Pereira, Sandrina

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

O

  1. Oei, Vincent Yi Sheng

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  2. Olweus, Johanna

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  3. Ozawa, Tatsuhiko

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

P

  1. Palacios, Daniel

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  2. Param, Nesteene J.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  3. Pardoll, Drew M.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  4. Piao, Xiuhong

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  5. Pishesha, Novalia

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  6. Ploegh, Hidde L.

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  7. Prchal-Murphy, Michaela

    1. Research Articles | AuthorChoice
      NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
      Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
      Cancer Immunol Res April 1 2018 6 (4) 458-466; DOI:10.1158/2326-6066.CIR-17-0183

      Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

  8. Prinz, Daniela

    1. Research Articles | AuthorChoice
      NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
      Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
      Cancer Immunol Res April 1 2018 6 (4) 458-466; DOI:10.1158/2326-6066.CIR-17-0183

      Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

  9. Putoczki, Tracy L.

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  10. Putz, Eva Maria

    1. Research Articles | AuthorChoice
      NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
      Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
      Cancer Immunol Res April 1 2018 6 (4) 458-466; DOI:10.1158/2326-6066.CIR-17-0183

      Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

R

  1. Rabadan, Raul

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  2. Rashidian, Mohammad

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  3. Reiner, Gabrielle L.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  4. Richman, Sarah A.

    1. Letters to the Editor
      Neurotoxicity Associated with a High-Affinity GD2 CAR—Response
      Sarah A. Richman and Michael C. Milone
      Cancer Immunol Res April 1 2018 6 (4) 496-497; DOI:10.1158/2326-6066.CIR-18-0090

  5. Rodrigues, Neidy V.

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

  6. Rossi, Ferdinand

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

S

  1. Saenger, Yvonne M.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  2. Santamaria-Barria, Juan

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  3. Schutz, Fabio A.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  4. Seifert, Adrian M.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  5. Servos, Mariah M.

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

  6. Sexl, Veronika

    1. Research Articles | AuthorChoice
      NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
      Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
      Cancer Immunol Res April 1 2018 6 (4) 458-466; DOI:10.1158/2326-6066.CIR-17-0183

      Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

  7. Sharabi, Andrew B.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  8. Shitaoka, Kiyomi

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  9. Sieber, Oliver M.

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  10. Siernicka, Marta

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  11. Silva-Santos, Bruno

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

  12. Sivick, Kelsey E.

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  13. Stack, Edward C.

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  14. Steinharter, John A.

    1. Research Articles
      Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
      Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott and Toni K. Choueiri
      Cancer Immunol Res April 1 2018 6 (4) 402-408; DOI:10.1158/2326-6066.CIR-17-0220

      mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

  15. Sugiyama, Daisuke

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  16. Sukegawa, Kenta

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

T

  1. Taback, Bret

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

  2. Takamatsu, Yasushi

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  3. Tanemura, Atsushi

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  4. Tani, Kenzaburo

    1. Research Articles
      Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
      Kiyomi Shitaoka, Hiroshi Hamana, Hiroyuki Kishi, Yoshihiro Hayakawa, Eiji Kobayashi, Kenta Sukegawa, Xiuhong Piao, Fulian Lyu, Takuya Nagata, Daisuke Sugiyama, Hiroyoshi Nishikawa, Atsushi Tanemura, Ichiro Katayama, Mutsunori Murahashi, Yasushi Takamatsu, Kenzaburo Tani, Tatsuhiko Ozawa and Atsushi Muraguchi
      Cancer Immunol Res April 1 2018 6 (4) 378-388; DOI:10.1158/2326-6066.CIR-17-0489

      Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

  5. Theodros, Debebe

    1. Research Articles | AuthorChoice
      TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
      Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky Jr, Drew M. Pardoll and Charles G. Drake
      Cancer Immunol Res April 1 2018 6 (4) 422-433; DOI:10.1158/2326-6066.CIR-17-0263

      Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

  6. Tutt, Andrew

    1. Research Articles | AuthorChoice
      Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
      Neidy V. Rodrigues, Daniel V. Correia, Sofia Mensurado, Sandrina Nóbrega-Pereira, Ana deBarros, Fernanda Kyle-Cezar, Andrew Tutt, Adrian C. Hayday, Haakan Norell, Bruno Silva-Santos and Sérgio Dias
      Cancer Immunol Res April 1 2018 6 (4) 448-457; DOI:10.1158/2326-6066.CIR-17-0327

      Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

  7. Tyler, Paul M.

    1. Research Articles
      Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
      Michael Dougan, Jessica R. Ingram, Hee-Jin Jeong, Munir M. Mosaheb, Patrick T. Bruck, Lestat Ali, Novalia Pishesha, Olga Blomberg, Paul M. Tyler, Mariah M. Servos, Mohammad Rashidian, Quang-De Nguyen, Ulrich H. von Andrian, Hidde L. Ploegh and Stephanie K. Dougan
      Cancer Immunol Res April 1 2018 6 (4) 389-401; DOI:10.1158/2326-6066.CIR-17-0495

      Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

V

  1. Vitiello, Gerardo A.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

W

  1. Weber, Evan W.

    1. Letters to the Editor
      Neurotoxicity Associated with a High-Affinity GD2 CAR—Letter
      Robbie G. Majzner, Evan W. Weber, Rachel C. Lynn, Peng Xu and Crystal L. Mackall
      Cancer Immunol Res April 1 2018 6 (4) 494-495; DOI:10.1158/2326-6066.CIR-18-0089

  2. Winiarska, Magdalena

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  3. Witalisz-Siepracka, Agnieszka

    1. Research Articles | AuthorChoice
      NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
      Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
      Cancer Immunol Res April 1 2018 6 (4) 458-466; DOI:10.1158/2326-6066.CIR-17-0183

      Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

  4. Wouters, Merridee A.

    1. Research Articles
      Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
      Moritz F. Eissmann, Christine Dijkstra, Merridee A. Wouters, David Baloyan, Dmitri Mouradov, Paul M. Nguyen, Mercedes Davalos-Salas, Tracy L. Putoczki, Oliver M. Sieber, John M. Mariadason, Matthias Ernst and Frederick Masson
      Cancer Immunol Res April 1 2018 6 (4) 409-421; DOI:10.1158/2326-6066.CIR-17-0218

      Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

  5. Wu, Alan

    1. Research Articles
      Quantitative Analysis of Immune Infiltrates in Primary Melanoma
      Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, Gen Li, Danielle R. Davari, Alan Wu, Zoë Blake, Yan Lu, Kayleigh N. Askin, Anthea Monod, Camden L. Esancy, Edward C. Stack, Dan Tong Jia, Paul M. Armenta, Yichun Fu, Daisuke Izaki, Bret Taback, Raul Rabadan, Howard L. Kaufman, Charles G. Drake, Basil A. Horst and Yvonne M. Saenger
      Cancer Immunol Res April 1 2018 6 (4) 481-493; DOI:10.1158/2326-6066.CIR-17-0360

      Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

X

  1. Xu, Peng

    1. Letters to the Editor
      Neurotoxicity Associated with a High-Affinity GD2 CAR—Letter
      Robbie G. Majzner, Evan W. Weber, Rachel C. Lynn, Peng Xu and Crystal L. Mackall
      Cancer Immunol Res April 1 2018 6 (4) 494-495; DOI:10.1158/2326-6066.CIR-18-0089

Y

  1. Yang, Weiwen

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

Z

  1. Zagozdzon, Radoslaw

    1. Research Articles | AuthorChoice
      Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
      Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
      Cancer Immunol Res April 1 2018 6 (4) 467-480; DOI:10.1158/2326-6066.CIR-17-0207

      Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

  2. Zeng, Shan

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  3. Zhang, Jennifer Q.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

  4. Zhao, Julia N.

    1. Research Articles
      Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
      Jennifer Q. Zhang, Shan Zeng, Gerardo A. Vitiello, Adrian M. Seifert, Benjamin D. Medina, Michael J. Beckman, Jennifer K. Loo, Juan Santamaria-Barria, Joanna H. Maltbaek, Nesteene J. Param, John A. Moral, Julia N. Zhao, Vinod Balachandran, Ferdinand Rossi, Cristina R. Antonescu and Ronald P. DeMatteo
      Cancer Immunol Res April 1 2018 6 (4) 434-447; DOI:10.1158/2326-6066.CIR-17-0345

      The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8+ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

Back to top
Previous
Cancer Immunology Research: 6 (4)
April 2018
Volume 6, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Editorial Board (PDF)

Sign up for alerts

Advertisement
  • Home
  • Alerts
  • Feedback
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement